Science Sparks @ ACTREC
16 March 2026Publications
- 1. Nair S, Shetty R, Bhawalkar A, Joshi P, Singh A, Singhavi H, Sharma JK, Sinha S, Kumar A, Laskar SG, Joshi A, Chaturvedi P (2026). Impact of infratemporal fossa clearance on survival in advanced buccal mucosa cancers. Head Neck.
- 2. Saha S, Trivedi B, Ojha S, Ambulkar R, Nambiar A, Sarwade K, Kumar A, Kannan S (2026). Towards rational blood utilization: development of a transfusion risk prediction tool for onco-surgical practice. World Journal of Surgical Oncology
- 3. Agate S, Patil S, Sarade M, Lokhande D, Bhojane S, Angane S, Das D, Banavali S, Chaturvedi P, Budukh A (2026). Overall survival of oral cancer from the population-based cancer registries of the Konkan area, Maharashtra, India. BMC Cancer.
- 4. Moirangthem R, Manjrekar A, Pullat GB, Golapkar SV, Margale RS, Sagare S, Talukdar D, Chakraborty N, Pathak R, Pradhan S, Krishnatreya M, Panse N, Dikshit R, Soerjomataram I, Gupta S, Mhatre S (2026). Association of chewing tobacco and the risk of breast cancer in Indian women: A multicentre case-control study. International Journal of Breast Cancer.
- 5. Saha P, Varyani R, Hole A, Joshi P, Waghmare MS, Singh A, Chaturvedi P, Govekar R, CM Krishna (2026). Multimodal serum profiling for early detection and risk assessment of oral potentially malignant disorders and oral cancer. Analytical Chemistry.
- 6. Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P... Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M...etal..., Jabado N, Erker C (2026). Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study. Clinical Cancer Research.
- 7. Ostwal V, Parulekar M, Naughane D, Ramaswamy A, Garkal T, John G, Mandavkar S, Bhargava P, Gupta A, Kapoor A, Joshi P, Shetty O, Srinivas S, Kannan S, Chaugule D, Jadhav P, Joshi A, Ghosh J, Noronha V, Menon N, Prabhash K, Khandare M, More S, Gaud S, Banavali S, Gupta S (2026). Carica papaya leaf extract to improve chemotherapy-induced thrombocytopenia: A phase III triple-blinded, randomized, placebo-controlled, multicentric trial. JCO Global Oncology.(3):e2500386.
- 8. Kannan N, Achrekar A, Terse V, Gawde V, Joshi S, Bhanshe P, Chaudhary S, Salunke P, Ghogale S, Deshpande N, Shetty D, Shetty A, Mirgh S, Nayak L, Gokarn A, Punatar S, Jain H, Bagal B, Sengar M, Khattry N, Rajpal S, Chatterjee G, Tembhare P, Subramanian PG, Patkar N (2026). Acute myeloid leukaemia (AML) harbouring KMT2A-PTD: should it be considered as a myelodysplasia-related abnormality? Journal of Clinical Pathology.
- 9. Yegnaswamy S, Selvaa Kumar C, Aldaais E, Shinde I (2026). Structural resilience of conserved-site mutations in the MERS-CoV membrane protein: insights into stability and conformational dynamics. Journal of Biomolecular Structure and Dynamics.
- 10. Inchanalkar M, Chavda R, Gawde J, Patil A, Kaushal RK, Mahimkar MB (2026). Upregulation of Derlin 3 (DERL3) protein expression is associated with Oral Cancer progression and is independent of promoter hypermethylation. BMC Cancer.
Video of the Week
25 Years of LKB1/STK11 Tumor Supressor: From Immunotherapy Resistance to Cachexia
Upcoming Events
March 25-27, 2026
At Lecture Hall, 2nd Floor, Golden Jubilee Building, Tata Memorial Centre, Mumbai
March 28, 2026
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai
April 11, 2026
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai
Do You Know?
In 2001, Results of a clinical trial showed that the drug imatinib mesylate, which targets a unique protein produced by the Philadelphia chromosome, is effective against chronic myelogenous leukemia (CML).
Cancer News
MedicalXpress, 12/03/2026
As a proof of concept, the researchers used the method on solid tumor biopsies. They found around 120 potential new therapeutic targets, molecules that might one day be dialed up or down to restore balance in the cell's editing machinery...
Sciencedaily, 12/03/2026
Scientists have discovered that a rare “mirror-image” version of the amino acid cysteine can dramatically slow the growth of certain cancers while leaving healthy cells largely untouched. Unlike most anticancer treatments that harm normal tissues, this moleculecalled D-cysteine...
SciTechDaily, 08/03/2026
Genetic and epigenetic changes can reactivate biological programs that were active during the early development of tissues and organs but were later shut down. When these programs become active again in the wrong context, they can drive tumor formation...
© 2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)